SI3018145T1 - Sredstva in metode za zdravljenje dlbcl - Google Patents
Sredstva in metode za zdravljenje dlbcl Download PDFInfo
- Publication number
- SI3018145T1 SI3018145T1 SI201131489T SI201131489T SI3018145T1 SI 3018145 T1 SI3018145 T1 SI 3018145T1 SI 201131489 T SI201131489 T SI 201131489T SI 201131489 T SI201131489 T SI 201131489T SI 3018145 T1 SI3018145 T1 SI 3018145T1
- Authority
- SI
- Slovenia
- Prior art keywords
- composition
- dose
- use according
- time period
- dlbcl
- Prior art date
Links
- 206010012818 diffuse large B-cell lymphoma Diseases 0.000 title claims abstract 5
- 238000000034 method Methods 0.000 title claims abstract 3
- 208000031671 Large B-Cell Diffuse Lymphoma Diseases 0.000 claims abstract 4
- 206010025323 Lymphomas Diseases 0.000 claims abstract 4
- 206010028980 Neoplasm Diseases 0.000 claims 4
- 210000001165 lymph node Anatomy 0.000 claims 3
- 210000000988 bone and bone Anatomy 0.000 claims 2
- 210000003169 central nervous system Anatomy 0.000 claims 2
- 210000000481 breast Anatomy 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 230000000973 chemotherapeutic effect Effects 0.000 claims 1
- 238000002512 chemotherapy Methods 0.000 claims 1
- 210000001035 gastrointestinal tract Anatomy 0.000 claims 1
- 210000004185 liver Anatomy 0.000 claims 1
- 210000004072 lung Anatomy 0.000 claims 1
- 230000000306 recurrent effect Effects 0.000 claims 1
- 210000000952 spleen Anatomy 0.000 claims 1
- 210000001519 tissue Anatomy 0.000 claims 1
- 102100024222 B-lymphocyte antigen CD19 Human genes 0.000 abstract 3
- 101000980825 Homo sapiens B-lymphocyte antigen CD19 Proteins 0.000 abstract 3
- 210000001744 T-lymphocyte Anatomy 0.000 abstract 2
- 210000004027 cell Anatomy 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Biomedical Technology (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Steroid Compounds (AREA)
- Carbon And Carbon Compounds (AREA)
Claims (14)
1. Sestava, ki vsebuje bispecifično protitelo CD19xCD3 za uporabo pri metodi zdravljenja tumorske mase tkiva limfnih vozlov in/ali ekstranodalnega limfoma, ki ga povzroča difuzni velikocelični limfom B (DLBCL) pri bolniku, pri katerem je rak odporen proti kemoterapevtskemu zdravljenju in/ali recidiven po zdravljenju s kemoterapijo.
2. Sestava za uporabo v skladu s patentnim zahtevkom 1, pri čemer je za tumorsko maso značilno, da so tumorji večji od 10 x 10 mm.
3. Sestava za uporabo v skladu s patentnim zahtevkom 1 ali 2, pri čemer tkivo limfnih vozlov vključuje bezgavke in/ali vranico.
4. Sestava za uporabo v skladu s patentnim zahtevkom 1 ali 2, pri čemer ekstranodalni limfom vključuje osrednji živčni sistem (CNS), kožno tkivo, dojke, pljuča, jetra, gastrointestinalni trakt, genitourinarni trakt, očesno tkivo, kostni mozeg in/ali kosti.
5. Sestava za uporabo iz katerega koli prejšnjega patentnega zahtevka, pri čemer se prvi odmerek sestava dovaja za prvo časovno obdobje in nato se drugi odmerek sestava dovaja za drugo časovno obdobje, pri čemer drugi odmerek presega prvega.
6. Sestava za uporabo v skladu s patentnim zahtevkom 5, pri čemer je omenjeni prvi odmerek med 1 in 15 pg/m2/d.
7. Sestava za uporabo v skladu s patentnim zahtevkom 5 ali 6, pri čemer je omenjeni drugi odmerek med 15 in 60 pg/m2/d.
8. Sestava za uporabo v skladu s patentnim zahtevkom 5, ki po prvem in drugem odmerku za prvo in drugo časovno obdobje nadalje obsega dovajanje tretjega odmerka sestava za tretje časovno obdobje.
9. Sestava za uporabo v skladu s patentnim zahtevkom 8, pri čemer tretje časovno obdobje presega prvo in drugo časovno obdobje, v katerem drugi odmerek presega navedeni prvi odmerek.
10. Sestava za uporabo v skladu s patentnim zahtevkom 8 ali 9, pri čemer tretji odmerek presega prvi in drugi odmerek.
11. Sestava za uporabo v skladu s katerim koli patentnim zahte
navedeni prvi odmerek med 1 in 15 pg/m2/d oz. prednostno 5 pg/m2/d.
12. Sestava za uporabo v skladu s katerim koli patentnim zahtevkom od 8 do 11, pri čemer je navedeni drugi odmerek med 1 in 15 pg/m2/d oz. prednostno 15 pg/m2/d.
13. Sestava za uporabo v skladu s katerim koli patentnim zahtevkom od 8 do 12, pri čemer je navedeni tretji odmerek med 15 in 60 pg/m2/d oz. prednostno 60 pg/m2/d.
14. Sestava za uporabo v skladu s katerim koli od patentnih zahtevkov od 1 do 4, pri čemer je protitelo med zdravljenjem odmerjeno v konstantnem odmerku, izbranem iz skupine, ki sestoji iz 5 pg/m2/d, 15 pg/m2/d ali 60 pg/m2/d oz. prednostno 60 pg/m2/d.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US40710710P | 2010-10-27 | 2010-10-27 | |
| EP15195076.3A EP3018145B1 (en) | 2010-10-27 | 2011-10-27 | Means and methods for treating dlbcl |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SI3018145T1 true SI3018145T1 (sl) | 2018-08-31 |
Family
ID=45023802
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SI201130709T SI2632954T2 (sl) | 2010-10-27 | 2011-10-27 | Sredstva in postopki za zdravljenje dlbcl |
| SI201131489T SI3018145T1 (sl) | 2010-10-27 | 2011-10-27 | Sredstva in metode za zdravljenje dlbcl |
| SI201131861T SI3412687T1 (sl) | 2010-10-27 | 2011-10-27 | Postopek zdravljenja DLBCL |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SI201130709T SI2632954T2 (sl) | 2010-10-27 | 2011-10-27 | Sredstva in postopki za zdravljenje dlbcl |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SI201131861T SI3412687T1 (sl) | 2010-10-27 | 2011-10-27 | Postopek zdravljenja DLBCL |
Country Status (32)
| Country | Link |
|---|---|
| US (2) | US9192665B2 (sl) |
| EP (3) | EP3412687B1 (sl) |
| JP (3) | JP5997168B2 (sl) |
| KR (1) | KR101889995B1 (sl) |
| CN (2) | CN103459425B (sl) |
| AU (1) | AU2011322581B2 (sl) |
| CA (1) | CA2815119C (sl) |
| CL (1) | CL2013001138A1 (sl) |
| CR (1) | CR20130245A (sl) |
| CY (3) | CY1117155T1 (sl) |
| DK (3) | DK3412687T3 (sl) |
| EA (1) | EA032139B1 (sl) |
| ES (3) | ES2563439T5 (sl) |
| HK (1) | HK1188229A1 (sl) |
| HR (2) | HRP20151444T4 (sl) |
| HU (3) | HUE037786T2 (sl) |
| IL (3) | IL225924A (sl) |
| LT (2) | LT3412687T (sl) |
| MA (1) | MA34619B1 (sl) |
| ME (1) | ME02311B (sl) |
| MY (1) | MY163057A (sl) |
| NZ (2) | NZ609201A (sl) |
| PH (1) | PH12013500826A1 (sl) |
| PL (3) | PL2632954T5 (sl) |
| PT (3) | PT3018145T (sl) |
| RS (3) | RS60094B1 (sl) |
| SG (1) | SG189869A1 (sl) |
| SI (3) | SI2632954T2 (sl) |
| SM (3) | SMT202000232T1 (sl) |
| TR (1) | TR201808019T4 (sl) |
| UA (1) | UA111175C2 (sl) |
| WO (1) | WO2012055961A1 (sl) |
Families Citing this family (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2006114115A1 (de) | 2005-04-26 | 2006-11-02 | Trion Pharma Gmbh | Kombination von antikörpern mit glukokortikoiden zur behandlung von krebs |
| LT3412687T (lt) * | 2010-10-27 | 2020-07-27 | Amgen Research (Munich) Gmbh | Didžiųjų b ląstelių difuzinės limfomos gydymo būdai |
| HRP20170814T4 (hr) * | 2010-11-10 | 2024-05-10 | Amgen Research (Munich) Gmbh | Prevencija nuspojava uzrokovanih cd3 specifičnim veznim domenama |
| JO3529B1 (ar) * | 2013-02-08 | 2020-07-05 | Amgen Res Munich Gmbh | مضاد التصاق خلايا الدم البيض من أجل التخفيف من الاثار السلبية الممكنة الناتجة عن مجالات ارتباط cd3- المحدد |
| CN105829349B (zh) * | 2013-10-15 | 2023-02-03 | 斯克利普斯研究所 | 肽嵌合抗原受体t细胞开关和其用途 |
| WO2016154621A1 (en) | 2015-03-26 | 2016-09-29 | The California Institute For Biomedical Research | SWITCHABLE NON-scFv CHIMERIC RECEPTORS, SWITCHES, AND USES THEREOF |
| WO2016168773A2 (en) | 2015-04-15 | 2016-10-20 | The California Institute For Biomedical Research | Optimized pne-based chimeric receptor t cell switches and uses thereof |
| CN107995913B (zh) | 2015-05-18 | 2022-02-11 | T细胞受体治疗公司 | 使用融合蛋白对tcr重编程的组合物和方法 |
| EP3362479A4 (en) * | 2015-10-13 | 2019-05-15 | Eureka Therapeutics, Inc. | FOR HUMANESE CD19 SPECIFIC ANTIBODY AGENTS AND USES THEREOF |
| WO2018014001A1 (en) | 2016-07-14 | 2018-01-18 | Fred Hutchinson Cancer Research Center | Multiple bi-specific binding domain constructs with different epitope binding to treat cancer |
| CN109715668A (zh) | 2016-08-02 | 2019-05-03 | T细胞受体治疗公司 | 用于使用融合蛋白进行tcr重编程的组合物和方法 |
| HUE054080T2 (hu) | 2016-10-07 | 2021-08-30 | Tcr2 Therapeutics Inc | Készítmények és eljárások a T-sejt receptorok átprogramozására fúziós fehérjék felhasználásával |
| WO2018075807A1 (en) | 2016-10-19 | 2018-04-26 | California Institute For Biomedical Research | Chimeric antigen receptor effector cell switches with humanized targeting moieties and/or optimized chimeric antigen receptor interacting domains and uses thereof |
| EP3544996A2 (en) | 2016-11-22 | 2019-10-02 | TCR2 Therapeutics Inc. | Compositions and methods for tcr reprogramming using fusion proteins |
| US10537585B2 (en) | 2017-12-18 | 2020-01-21 | Dexcel Pharma Technologies Ltd. | Compositions comprising dexamethasone |
| US11865081B2 (en) | 2017-12-29 | 2024-01-09 | Virogin Biotech Canada Ltd. | Oncolytic viral delivery of therapeutic polypeptides |
| US20220023430A1 (en) * | 2018-11-13 | 2022-01-27 | Lipoxen Technologies Limited | Glycopolysialylation of blinatumomab |
| EP3962490A4 (en) * | 2019-05-03 | 2023-01-25 | Kite Pharma, Inc. | METHOD OF ADMINISTRATION OF CHIMERIC ANTIGEN RECEPTOR IMMUNOTHERAPY |
| JP7137696B2 (ja) | 2019-05-14 | 2022-09-14 | プロヴェンション・バイオ・インコーポレイテッド | １型糖尿病を予防するための方法および組成物 |
| WO2020236792A1 (en) | 2019-05-21 | 2020-11-26 | Novartis Ag | Cd19 binding molecules and uses thereof |
| JP2023530109A (ja) | 2020-06-11 | 2023-07-13 | プロヴェンション・バイオ・インコーポレイテッド | １型糖尿病を予防するための方法および組成物 |
| US20220184208A1 (en) * | 2020-12-04 | 2022-06-16 | Morphosys Ag | Anti-cd19 combination therapy |
| EP4284512B1 (en) | 2021-01-28 | 2025-03-26 | Regeneron Pharmaceuticals, Inc. | Compositions and methods for treating cytokine release syndrome |
| KR20250004700A (ko) | 2022-04-11 | 2025-01-08 | 리제너론 파마슈티칼스 인코포레이티드 | 보편적 종양 세포 사멸을 위한 조성물 및 방법 |
| WO2024173830A2 (en) | 2023-02-17 | 2024-08-22 | Regeneron Pharmaceuticals, Inc. | Induced nk cells responsive to cd3/taa bispecific antibodies |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU612370B2 (en) | 1987-05-21 | 1991-07-11 | Micromet Ag | Targeted multifunctional proteins |
| BRPI9909860B8 (pt) | 1998-04-21 | 2021-05-25 | Amgen Res Munich Gmbh | polipeptídeo multifuncional de cadeia simples, polinucleotídeo, vetor, célula procariótica, de levedura ou unicelular, composição, usos de polipeptídeo e polinucleotídeo e métodos para preparo do referido polipeptídeo e para identificação de ativadores ou inibidores de ativação ou estimulação das células t |
| CN100509850C (zh) | 2003-05-31 | 2009-07-08 | 麦克罗梅特股份公司 | 用于治疗b细胞相关疾病的包含双特异性抗cd3、抗cd19抗体构建体的药物组合物 |
| AU2004293182B2 (en) | 2003-11-28 | 2010-02-18 | Amgen Research (Munich) Gmbh | Compositions comprising polypeptides |
| AU2006214121B9 (en) | 2005-02-15 | 2013-02-14 | Duke University | Anti-CD19 antibodies and uses in oncology |
| WO2006114115A1 (de) * | 2005-04-26 | 2006-11-02 | Trion Pharma Gmbh | Kombination von antikörpern mit glukokortikoiden zur behandlung von krebs |
| CA2633594C (en) | 2005-12-16 | 2021-10-26 | Micromet Ag | Means and methods for the treatment of tumorous diseases |
| CN101331151A (zh) * | 2005-12-16 | 2008-12-24 | 麦克罗梅特股份公司 | 治疗肿瘤性疾病的方式和方法 |
| KR101456728B1 (ko) | 2006-09-08 | 2014-10-31 | 메디뮨 엘엘씨 | 인간화 항-ｃｄ19 항체, 및 이것의 종양학, 이식 및 자가면역 질환의 치료에서의 용도 |
| AU2008234020B2 (en) | 2007-04-03 | 2013-02-07 | Amgen Research (Munich) Gmbh | Cross-species-specific CD3-epsilon binding domain |
| SI2342227T1 (sl) * | 2008-11-07 | 2015-12-31 | Amgen Research (Munich) Gmbh | Zdravljenje akutne limfoblastne levkemije |
| SI2493503T2 (sl) | 2009-10-27 | 2021-04-30 | Amgen Research (Munich) Gmbh | Režim odmerjanja za dajanje cd19xcd3 bispecifičnega protitelesa |
| LT3412687T (lt) * | 2010-10-27 | 2020-07-27 | Amgen Research (Munich) Gmbh | Didžiųjų b ląstelių difuzinės limfomos gydymo būdai |
-
2011
- 2011-10-27 LT LTEP18164175.4T patent/LT3412687T/lt unknown
- 2011-10-27 SM SM20200232T patent/SMT202000232T1/it unknown
- 2011-10-27 PT PT151950763T patent/PT3018145T/pt unknown
- 2011-10-27 PL PL11787633T patent/PL2632954T5/pl unknown
- 2011-10-27 WO PCT/EP2011/068851 patent/WO2012055961A1/en active Application Filing
- 2011-10-27 HU HUE15195076A patent/HUE037786T2/hu unknown
- 2011-10-27 TR TR2018/08019T patent/TR201808019T4/tr unknown
- 2011-10-27 PL PL18164175T patent/PL3412687T3/pl unknown
- 2011-10-27 AU AU2011322581A patent/AU2011322581B2/en active Active
- 2011-10-27 DK DK18164175.4T patent/DK3412687T3/da active
- 2011-10-27 SI SI201130709T patent/SI2632954T2/sl unknown
- 2011-10-27 JP JP2013535437A patent/JP5997168B2/ja active Active
- 2011-10-27 EP EP18164175.4A patent/EP3412687B1/en not_active Revoked
- 2011-10-27 PT PT181641754T patent/PT3412687T/pt unknown
- 2011-10-27 ES ES11787633T patent/ES2563439T5/es active Active
- 2011-10-27 MA MA35841A patent/MA34619B1/fr unknown
- 2011-10-27 EP EP11787633.4A patent/EP2632954B2/en active Active
- 2011-10-27 SG SG2013026828A patent/SG189869A1/en unknown
- 2011-10-27 LT LTEP15195076.3T patent/LT3018145T/lt unknown
- 2011-10-27 ES ES15195076.3T patent/ES2675299T3/es active Active
- 2011-10-27 CN CN201180063222.2A patent/CN103459425B/zh active Active
- 2011-10-27 RS RS20200368A patent/RS60094B1/sr unknown
- 2011-10-27 PL PL15195076T patent/PL3018145T3/pl unknown
- 2011-10-27 ME MEP-2015-213A patent/ME02311B/me unknown
- 2011-10-27 NZ NZ609201A patent/NZ609201A/en unknown
- 2011-10-27 SM SM20180319T patent/SMT201800319T1/it unknown
- 2011-10-27 ES ES18164175T patent/ES2787044T3/es active Active
- 2011-10-27 HU HUE11787633A patent/HUE027678T2/en unknown
- 2011-10-27 RS RS20180624A patent/RS57260B1/sr unknown
- 2011-10-27 PT PT117876334T patent/PT2632954E/pt unknown
- 2011-10-27 HU HUE18164175A patent/HUE048639T2/hu unknown
- 2011-10-27 US US13/881,889 patent/US9192665B2/en active Active
- 2011-10-27 SI SI201131489T patent/SI3018145T1/sl unknown
- 2011-10-27 RS RS20160027A patent/RS54525B2/sr unknown
- 2011-10-27 CA CA2815119A patent/CA2815119C/en active Active
- 2011-10-27 DK DK15195076.3T patent/DK3018145T3/en active
- 2011-10-27 PH PH1/2013/500826A patent/PH12013500826A1/en unknown
- 2011-10-27 CN CN201510672546.6A patent/CN105251003B/zh active Active
- 2011-10-27 NZ NZ701715A patent/NZ701715A/en unknown
- 2011-10-27 MY MYPI2013001269A patent/MY163057A/en unknown
- 2011-10-27 EA EA201390387A patent/EA032139B1/ru not_active IP Right Cessation
- 2011-10-27 UA UAA201306486A patent/UA111175C2/uk unknown
- 2011-10-27 EP EP15195076.3A patent/EP3018145B1/en active Active
- 2011-10-27 KR KR1020137013384A patent/KR101889995B1/ko active Active
- 2011-10-27 SI SI201131861T patent/SI3412687T1/sl unknown
- 2011-10-27 DK DK11787633.4T patent/DK2632954T4/da active
-
2013
- 2013-04-24 IL IL225924A patent/IL225924A/en active IP Right Grant
- 2013-04-25 CL CL2013001138A patent/CL2013001138A1/es unknown
- 2013-05-27 CR CR20130245A patent/CR20130245A/es unknown
-
2014
- 2014-02-14 HK HK14101399.9A patent/HK1188229A1/xx unknown
-
2015
- 2015-10-16 US US14/885,404 patent/US10696744B2/en active Active
- 2015-12-31 HR HRP20151444TT patent/HRP20151444T4/hr unknown
-
2016
- 2016-01-29 CY CY20161100083T patent/CY1117155T1/el unknown
- 2016-02-17 SM SM201600050T patent/SMT201600050B/xx unknown
- 2016-06-01 JP JP2016110083A patent/JP6254220B2/ja active Active
-
2017
- 2017-11-29 JP JP2017228716A patent/JP6522722B2/ja active Active
- 2017-12-05 IL IL256110A patent/IL256110B/en active IP Right Grant
-
2018
- 2018-05-16 CY CY20181100508T patent/CY1120227T1/el unknown
- 2018-06-05 HR HRP20180882TT patent/HRP20180882T1/hr unknown
- 2018-07-25 IL IL260774A patent/IL260774B/en active IP Right Grant
-
2020
- 2020-05-08 CY CY20201100425T patent/CY1123251T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SI3018145T1 (sl) | Sredstva in metode za zdravljenje dlbcl | |
| Canter et al. | Radiotherapy enhances natural killer cell cytotoxicity and localization in pre-clinical canine sarcomas and first-in-dog clinical trial | |
| Vuckovic et al. | Bone marrow transplantation generates T cell–dependent control of myeloma in mice | |
| PH12018501220A1 (en) | Bispecific molecules having immunoreactivity with pd-1 and ctla-4, and methods of use thereof | |
| NZ619576A (en) | Compositions and methods for the treatment of infections and tumors | |
| MX2024013016A (es) | Anticuerpos anti-pd1 para usarse en el tratamiento del cancer | |
| RU2017145558A (ru) | Комбинация антагониста pd-1 и олигонуклеотида типа cpg-c для лечения рака | |
| BR112017019785A2 (pt) | anticorpos terapêuticos e seus usos | |
| JP2018516911A5 (sl) | ||
| WO2018094190A3 (en) | Gut microbiota and treatment of cancer | |
| EP3525801A1 (en) | Medical uses of exosomes | |
| EA201171195A8 (ru) | Конъюгаты, частицы, композиции "полимер-агент" и способы их применения | |
| WO2012149412A3 (en) | Anti-endoglin (cd105) antibodies, immunoconjugates, and uses thereof | |
| EP4335511A3 (en) | Small molecule trail gene induction by normal and tumor cells as an anticancer therapy | |
| JP2012019788A5 (sl) | ||
| PH12020551447A1 (en) | Antibodies | |
| Jin et al. | Tumor-specific antibody, cetuximab, enhances the in situ vaccine effect of radiation in immunologically cold head and neck squamous cell carcinoma | |
| MX2009010269A (es) | Metodos de tratamiento del cancer mediante administracion de combinaciones de interleucina-18 humana. | |
| Zhang et al. | RETRACTED ARTICLE: JAK-STAT Domain Enhanced MUC1-CAR-T Cells Induced Esophageal Cancer Elimination | |
| D’Alterio et al. | New CXCR4 antagonist peptide R (Pep R) improves standard therapy in colorectal cancer | |
| WO2013170263A3 (en) | Dosage and administration of bispecific scfv conjugates in combination with anti-cancer therapeutics | |
| WO2021062085A8 (en) | Dosing for treatment with anti-tigit and anti-pd-l1 antagonist antibodies | |
| RU2014145234A (ru) | Система и способ для многофазного высвобождения факторов роста | |
| PH12020551454A1 (en) | Anti-cd25 for tumour specific cell depletion | |
| MX2021003047A (es) | Nanosondas ups de doble modalidad para imagenologia de acidosis tumoral. |